These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 27800022)
1. Evidence for the use of pimavanserin in the treatment of Parkinson's disease psychosis. Sarva H; Henchcliffe C Ther Adv Neurol Disord; 2016 Nov; 9(6):462-473. PubMed ID: 27800022 [TBL] [Abstract][Full Text] [Related]
3. Pimavanserin and Parkinson's Disease Psychosis: A Narrative Review. Rissardo JP; Durante Í; Sharon I; Fornari Caprara AL Brain Sci; 2022 Sep; 12(10):. PubMed ID: 36291220 [TBL] [Abstract][Full Text] [Related]
4. Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin. Majlath Z; Obal I; Vecsei L CNS Neurol Disord Drug Targets; 2017; 16(3):234-243. PubMed ID: 27719624 [TBL] [Abstract][Full Text] [Related]
5. On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis. Hacksell U; Burstein ES; McFarland K; Mills RG; Williams H Neurochem Res; 2014 Oct; 39(10):2008-17. PubMed ID: 24682754 [TBL] [Abstract][Full Text] [Related]
6. Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis. Kianirad Y; Simuni T Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1161-1168. PubMed ID: 28817967 [TBL] [Abstract][Full Text] [Related]
7. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis. Meltzer HY; Mills R; Revell S; Williams H; Johnson A; Bahr D; Friedman JH Neuropsychopharmacology; 2010 Mar; 35(4):881-92. PubMed ID: 19907417 [TBL] [Abstract][Full Text] [Related]
8. Management of Parkinson's Disease Psychosis. Elsibai H; Kualleny M; Fandy TE Sr Care Pharm; 2022 Aug; 37(8):339-344. PubMed ID: 35879841 [No Abstract] [Full Text] [Related]
9. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Cummings J; Isaacson S; Mills R; Williams H; Chi-Burris K; Corbett A; Dhall R; Ballard C Lancet; 2014 Feb; 383(9916):533-40. PubMed ID: 24183563 [TBL] [Abstract][Full Text] [Related]
10. Psychosis in Parkinson's Disease: Current Treatment Options and Impact on Patients and Caregivers. Segal GS; Xie SJ; Paracha SU; Grossberg GT J Geriatr Psychiatry Neurol; 2021 Jul; 34(4):274-279. PubMed ID: 34219522 [TBL] [Abstract][Full Text] [Related]
11. Falls and Fractures in Patients with Parkinson's Disease-Related Psychosis Treated with Pimavanserin vs Atypical Antipsychotics: A Cohort Study. Layton JB; Forns J; Turner ME; Dempsey C; Bartsch JL; Anthony MS; Danysh HE; Ritchey ME; Demos G Drugs Real World Outcomes; 2022 Mar; 9(1):9-22. PubMed ID: 34718963 [TBL] [Abstract][Full Text] [Related]
12. Pimavanserin for the treatment of Parkinson's disease psychosis. Friedman JH Expert Opin Pharmacother; 2013 Oct; 14(14):1969-75. PubMed ID: 24016069 [TBL] [Abstract][Full Text] [Related]
13. Evaluating pimavanserin tartrate as a treatment in Parkinson's disease. Müller T Expert Opin Pharmacother; 2024 Oct; ():. PubMed ID: 39403823 [TBL] [Abstract][Full Text] [Related]
14. Evidence for using pimavanserin for the treatment of Parkinson's disease psychosis. Tampi RR; Tampi DJ; Young JJ; Balachandran S; Hoq RA; Manikkara G World J Psychiatry; 2019 Jun; 9(3):47-54. PubMed ID: 31211112 [TBL] [Abstract][Full Text] [Related]
15. Pimavanserin: A Truly Effective Treatment for Parkinson's Disease Psychosis? A Review of Interventions. Heim B; Peball M; Krismer F; Djamshidian A; Seppi K Neuropsychiatr Dis Treat; 2023; 19():1303-1312. PubMed ID: 37274140 [TBL] [Abstract][Full Text] [Related]